# SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

Study · id `cardio:ct-nct07344922` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07344922](<https://clinicaltrials.gov/study/NCT07344922>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07344922

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT07344922. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-11-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT07344922, source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)
- Started: 2022-09-01 (actual) (ClinicalTrials.gov record NCT07344922, source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)
- Primary completion: 2023-11-01 (actual) (ClinicalTrials.gov record NCT07344922, source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)
- Completion: 2023-12-01 (actual) (ClinicalTrials.gov record NCT07344922, source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07344922, source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07344922-2026-01-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
- Condition: Chronic Kidney Disease
- Condition: Anemia
- Condition: Cardiovascular Calcification
- Intervention (Drug): Dapagliflozin (10Mg Tab) along with standard medical therapy
- Intervention (Other): Placebo
- Lead sponsor: Mansoura University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Mansoura University (`cardio:org-mansoura-university`)

## Provenance

Content hash: 726e8c121ea47298dd7a11c7540e2067ca4febed9afa8775be97b31b65904b4c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
